Old Web
English
Sign In
Acemap
>
authorDetail
>
Stephen J. Rozzo
Stephen J. Rozzo
Princeton University
Medicine
Internal medicine
Tildrakizumab
Psoriasis
in patient
5
Papers
11
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study.
2021
Annals of the Rheumatic Diseases
Philip J. Mease
Saima Chohan
Ferran J García Fructuoso
Michael E. Luggen
Proton Rahman
Siba P. Raychaudhuri
Richard C. Chou
A.M. Mendelsohn
Stephen J. Rozzo
Alice B. Gottlieb
Show All
Source
Cite
Save
Citations (2)
Five-year efficacy and safety of tildrakizumab in patients with moderate to severe psoriasis who respond at week 28: pooled analyses of two randomised phase 3 clinical trials (reSURFACE 1 and reSURFACE 2).
2021
British Journal of Dermatology
Diamant Thaçi
Stefano Piaserico
R.B. Warren
Aditya K. Gupta
Wendy Cantrell
Z. Draelos
Peter Foley
Atsuyuki Igarashi
Richard G. Langley
A. Asahina
M. Young
M Falques
Ignasi Pau-Charles
A.M. Mendelsohn
Stephen J. Rozzo
Kristian Reich
Show All
Source
Cite
Save
Citations (7)
Dose escalation and associated costs in biologic treatment of psoriasis based on real-world data
2021
Journal of Medical Economics
Jerry Bagel
Brad P. Glick
Jashin J. Wu
Ishveen Chopra
Xue Song
Matthew Brouillette
A.M. Mendelsohn
Stephen J. Rozzo
George Han
Show All
Source
Cite
Save
Citations (1)
Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5-year extension of a phase 3 study (reSURFACE 1).
2021
Journal of Dermatology
Shinichi Imafuku
Hidemi Nakagawa
Atsuyuki Igarashi
Akimichi Morita
Yukari Okubo
Shigetoshi Sano
Yayoi Tada
Osamu Nemoto
Stephen J. Rozzo
Masaki Kawamura
Mamitaro Ohtsuki
Show All
Source
Cite
Save
Citations (0)
Efficacy and safety of tildrakizumab 100 mg for plaque psoriasis in patients randomised to treatment continuation vs treatment withdrawal with retreatment upon relapse in reSURFACE 1.
2021
Journal of The European Academy of Dermatology and Venereology
Wendy Cantrell
P. Lee
A.M. Mendelsohn
Stephen J. Rozzo
Wilson Liao
Show All
Source
Cite
Save
Citations (1)
1